M3Hep: a multimodal hepatotoxicity prediction model combining mitochondrial toxicity and masking strategy.

Journal: Toxicology mechanisms and methods
Published Date:

Abstract

Drug hepatotoxicity is one of the primary reasons for drug clinical trial failures and market withdrawals, with mitochondrial dysfunction being one of the mechanisms inducing drug hepatotoxicity. Manifestation of mitochondrial toxicity occurs when mitochondria are damaged or their functions are inhibited. This study introduces M3Hep, a novel multimodal framework that integrates SMILES, molecular graphs, and mitochondrial toxicity through a masking strategy to improve hepatotoxicity prediction. A total of 8,459 mitochondrial toxicity samples and 6,418 hepatotoxicity samples were collected for constructing the mitochondrial toxicity prediction model and M3Hep, respectively. To fully utilize the collected hepatotoxicity samples, this study developed a mitochondrial toxicity prediction model to predict mitochondrial toxicity for molecules without experimental mitochondrial toxicity data, achieving an AUC of 0.96 for the mitochondrial toxicity prediction model. The ablation study results of M3Hep indicate that incorporating mitochondrial toxicity enhances the performance of hepatotoxicity prediction models, further demonstrating the connection between mitochondrial toxicity and hepatotoxicity. M3Hep outperforms most baseline models across all metrics, with its AUC reaching up to 0.81. Moreover, in terms of the MCC metric, M3Hep surpasses all commonly used hepatotoxicity prediction tools collected, with a value of 0.49. In order to better understand the prediction mechanism of M3Hep, we conducted an interpretability analysis based on the GNNExplainer and SHAP methods.

Authors

  • Yang Liu
    Department of Computer Science, Hong Kong Baptist University, Hong Kong, China.
  • Yu Xie
    Department of Sociology, Princeton University, Princeton, New Jersey, USA.
  • Xiao Wang
    Research Centre of Basic Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Yingxu Liu
    Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
  • Simeng Zhang
    School of Economics and Management, Shenyang Agricultural University, Shenyang 110000, China.
  • Lidan Zheng
    Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
  • Qian Ge
    School of Science, China Pharmaceutical University, Nanjing 210009, PR China.
  • Lingxi Gu
    Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
  • Yanmin Zhang
    Department of Paediatric Cardiology, Shaanxi Institute for Pediatric Diseases, Affiliate Children's Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Jinfeng Liu
  • Yadong Chen
    Laboratory of Molecular Design and Drug Discovery, School of Science, China; Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198 Jiangsu, China.
  • Mengyi Lu
    Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, PR China. Electronic address: [email protected].
  • Haichun Liu
    Laboratory of Molecular Design and Drug Discovery, School of Science, China; Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198 Jiangsu, China.

Keywords

No keywords available for this article.